精华制药集团股份有限公司 独立董事2024年度达职报告 二、发表独立意见情况 本人于2021年2月8日当选公司独立董事,2024年度共计参加董事会会议6次, 对30个议案进行了审议,在认真听取有关人员汇报并进行必要质询后,本人对审 议的所有事项均投了赞成票,并对计提减值准备、关联交易等相关事宜发表了同 意的独立意见。 三、对公司进行调查的情况 2024年度,本人累计为上市公司工作时间为15天。通过多渠道了解公司基本 生产经营和财务状况,与公司董事、高管人员保持沟通,关注外部环境及市场变 化对公司的影响，关注传媒、网络有关公司的报道，及时获悉公司重大事项进展 情况，掌握公司的运行动态。 一、出席会议情况 2024 年度公司共召开了六次董事会及二次股东大会。本人出席董事会情况 如下: | 独立董事 | 应出席董 | 现场出席 | 以通讯方式参 | 委托出 | 缺席次 | | --- | --- | --- | --- | --- | --- | | 姓名 | 事会次数 | 次数 | 加会议次数 | 席次数 | 数 | | 王 脚 | 1 | | 5 | | | 本年度,本人按时出席董事会会议,并列席股东大会,认真 ...

精华制药（002349）公告，2024年营业收入14.02亿元，同比下降7.25%。归属于上市公司股东的净利润 2.13亿元，同比下降14.15%。基本每股收益0.2612元/股，同比下降14.14%。公司拟向全体股东每10股派 发现金红利0.8元(含税)，送红股0股(含税)，不以公积金转增股本。 ...

证券代码：002349 证券简称：精华制药 公告编号：2025-002 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"）原指定的信息披露媒体为《证 券时报》及巨潮资讯网（http://www.cninfo.com.cn）。因与《证券时报》签订的 信息披露服务协议于 2025 年 2 月 28 日到期，2025 年 3 月 1 日起公司指定信息披露 媒体变更为《中国证券报》及巨潮资讯网（http://www.cninfo.com.cn）。 关于变更指定信息披露媒体的公告 精华制药集团股份有限公司董事会 2025 年 3 月 1 日 公司所有公开披露的信息均以在《中国证券报》及巨潮资讯网 （http://www.cninfo.com.cn）上刊登的正式公告为准，敬请广大投资者知悉。 公司对《证券时报》以往提供的优质服务表示衷心的感谢！ 精华制药集团股份有限公司 特此公告。 ...

Financial Performance - Q3 2024 revenue reached ¥324,863,232.05, a slight increase of 0.17% year-over-year, while year-to-date revenue decreased by 6.65% to ¥1,045,172,312.93[2] - Net profit attributable to shareholders for Q3 2024 was ¥28,799,911.32, down 29.31% compared to the same period last year, with a year-to-date decline of 15.93% to ¥164,234,071.15[2] - Basic earnings per share for Q3 2024 was ¥0.0354, reflecting a decrease of 29.20% year-over-year, with year-to-date earnings per share at ¥0.2017, down 15.92%[2] - Total operating revenue for Q3 2024 was CNY 1,045,172,312.93, a decrease of 6.64% compared to CNY 1,119,659,192.47 in the same period last year[14] - Total operating profit for Q3 2024 was approximately CNY 228.94 million, a decrease of 11.0% compared to CNY 257.05 million in Q3 2023[15] - Net profit attributable to shareholders of the parent company was CNY 164.23 million, down 16.0% from CNY 195.35 million in the same period last year[15] - The total profit for Q3 2024 was CNY 225.21 million, a decrease of 12.3% from CNY 257.00 million in the same quarter last year[15] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥3,225,786,732.90, representing a 1.28% increase from the end of the previous year[2] - The company’s total liabilities decreased to CNY 324,604,048.05 from CNY 380,746,462.33, a reduction of 14.77%[12] - The total equity attributable to shareholders increased to CNY 2,535,754,992.57 from CNY 2,444,593,197.18, marking a growth of 3.76%[13] Cash Flow - Cash flow from operating activities for the year-to-date period was ¥182,850,167.68, down 6.68% compared to the previous year[2] - Cash inflow from investment activities was CNY 710.86 million, significantly up from CNY 158.90 million in the previous year[16] - Cash flow from financing activities resulted in a net outflow of CNY 102.69 million, compared to a net outflow of CNY 92.66 million in Q3 2023[17] - The company reported a total cash and cash equivalents balance of CNY 1.30 billion at the end of Q3 2024, an increase from CNY 835.57 million at the end of Q3 2023[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 113,299[8] - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[8] - The second-largest shareholder, Jiangsu Nantong Port Development Co., Ltd., holds 3.66% of the shares, totaling 29,826,020 shares[8] - The top ten shareholders include various institutional investors, with the Southern CSI 1000 ETF holding 0.83% of the shares, totaling 6,751,400 shares[9] - The company reported changes in the top ten shareholders due to securities lending activities, with no significant changes in ownership percentages[10] Research and Development - Research and development expenses for Q3 2024 were CNY 47,149,976.95, an increase from CNY 44,544,568.46 in the previous year, reflecting a focus on innovation[14] - The company plans to continue focusing on R&D and market expansion strategies to enhance future performance[2] - The company plans to continue expanding its market presence and investing in new product development to drive future growth[14] Other Financial Metrics - Non-operating income for Q3 2024 included government subsidies of ¥212,130.66 and fair value changes of financial assets totaling ¥1,227,878.13[3] - The company reported a significant decrease in financial expenses by 57.77% year-over-year, attributed to increased deposit income[6] - The company experienced a 320.87% increase in cash recovered from investments, totaling ¥656,137,829.10 year-to-date[6] - Cash received from borrowings decreased to 10,000,000.00, a 37.50% decline compared to the same period last year, attributed to reduced bank borrowings by subsidiaries[7] - The impact of exchange rate fluctuations on cash and cash equivalents was -509,977.64, a 117.47% decrease due to foreign currency exchange rate changes during the reporting period[7]

证券代码：002349 证券简称：精华制药 公告编号：2024-030 经营范围：冻干粉针剂、治疗用生物制品（注射用重组人白介素-2）的生产； 保健食品的生产；食品、日用化学品的销售；二类6840体外诊断试剂的生产；药 品技术的开发、转让、咨询；自营和代理各类商品及技术的进出口业务（国家限 定企业经营或禁止进出口的商品和技术除外）。（依法须经批准的项目，经相关 部门批准后方可开展经营活动）许可项目：消毒剂生产（不含危险化学品）；第 二类医疗器械生产；第三类医疗器械生产；第三类医疗器械经营；医护人员防护 用品生产（Ⅱ类医疗器械）（依法须经批准的项目，经相关部门批准后方可开展 经营活动，具体经营项目以审批结果为准）一般项目：消毒剂销售（不含危险化 学品）；日用口罩（非医用）生产；日用口罩（非医用）销售；第一类医疗器械 生产；第一类医疗器械销售；第二类医疗器械销售；医护人员防护用品批发（除 依法须经批准的项目外，凭营业执照依法自主开展经营活动） 精华制药集团股份有限公司 关于出售参股子公司剩余股权的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 一 ...

具体内容详见2024年10月11日《证券时报》、巨潮资讯网（www.cninfo.com.cn） 《关于出售参股子公司剩余股权的公告》。 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 精华制药集团股份有限公司（以下简称"公司"、"本公司"、"精华制药"） 第六届董事会第三次会议通知于2024年9月29日以传真、专人送达、邮件等形式 发出，会议于2024年10月10日（星期四）以现场和通讯相结合方式在公司会议室 召开。会议应出席董事7名，出席董事7名，公司监事、高级管理人员列席了会议， 会议的召开符合《中华人民共和国公司法》及《公司章程》的有关规定，会议的 召集、召开合法有效。会议由董事长尹红宇先生主持。 本次会议审议了以下议案： 1、审议通过了《关于出售参股子公司剩余股权的议案》。 证券代码：002349 证券简称：精华制药 公告编号：2024-029 精华制药集团股份有限公司 第六届董事会第三次会议决议公告 表决结果：7票赞成；0票弃权；0票反对。 特此公告。 精华制药集团股份有限公司董事会 2024 年 10 月 11 日 ...

Financial Performance - The company's operating revenue for the first half of 2024 was CNY 720,309,080.88, representing a decrease of 9.43% compared to CNY 795,349,522.37 in the same period last year[10]. - The net profit attributable to shareholders for the first half of 2024 was CNY 135,434,159.83, down 12.40% from CNY 154,607,331.58 year-on-year[10]. - The net cash flow from operating activities was CNY 96,830,578.06, a decline of 2.94% compared to CNY 99,763,312.02 in the previous year[10]. - Basic earnings per share for the first half of 2024 were CNY 0.1663, down 12.43% from CNY 0.1899 in the same period last year[10]. - The company achieved consolidated sales revenue of CNY 720.31 million, a decrease of 9.43% year-on-year[23]. - The net profit attributable to the parent company was CNY 135 million, down 12.40% compared to the previous year[23]. - Operating cash flow was CNY 96.83 million, reflecting a decrease of 2.94% year-on-year[25]. - The company reported a total comprehensive income of ¥135,434,159.83 for the current period, reflecting strong financial performance[116]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 3,185,002,097.79, showing no change compared to CNY 3,185,011,365.95 at the end of the previous year[10]. - The total liabilities decreased to CNY 319,609,649.79 from CNY 380,746,462.33, a reduction of about 16.1%[101]. - Owner's equity increased to CNY 2,865,392,448.00 from CNY 2,804,264,903.62, showing an increase of approximately 2.18%[101]. - The company reported a net asset value of ¥311,599,482.29 in accounts receivable, which is 9.78% of total assets, up from 7.81% last year[29]. - Cash and cash equivalents amounted to ¥995,045,780.54, representing 31.24% of total assets, an increase from 28.94%[29]. - The company reported a decrease in trading financial assets to ¥230,796,670.47 from ¥317,695,016.44, a decline of approximately 27.3%[99]. Research and Development - Research and development expenses increased to CNY 32,505,972.93, up 13.48% from CNY 28,779,866.14 year-over-year[106]. - The company completed the registration application for the sustained-release tablets of carbidopa and levodopa, which is currently under review[23]. - The company is committed to ongoing research and development of new products and technologies to meet market demands[189]. Market and Product Strategy - The company operates in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine, chemical raw materials, and biopharmaceuticals[14]. - Key products include Wang's Baocuo Pills and Ji Desheng Snake Medicine Tablets, both recognized as unique products with significant therapeutic applications[17]. - The company has established a dual-wheel growth strategy, integrating upstream herbal processing and downstream formulation processing[18]. - The company is focusing on enhancing its market profitability by optimizing production processes and reducing costs[23]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[118]. Environmental Compliance - The company has passed environmental impact assessments and obtained pollution discharge permits for its projects, with the latest permit valid until March 6, 2029[48]. - The company has implemented various pollution discharge standards, including those for air pollutants and wastewater, in compliance with national regulations[48]. - The company has established a comprehensive environmental management system in place to address air, water, and noise pollution across its facilities[48]. - The company invested approximately 16.71 million yuan in environmental governance and protection in the first half of 2024, primarily for solid waste disposal, wastewater pretreatment, and air pollution control facilities[61]. Risk Management - The company faces risks related to raw material procurement, sales price declines, product quality, and environmental safety, which are discussed in detail in the risk management section[1]. - The company is facing risks related to national regulations and industry policy changes, particularly in the pharmaceutical sector[36]. - The company invests significant funds annually in drug research and development, facing risks of increased costs and extended registration periods due to stricter regulations[39]. Shareholder Information - The company held its annual general meeting on May 17, 2024, with a 35.81% investor participation rate[43]. - The company plans not to distribute cash dividends or issue bonus shares for the reporting period[1]. - The largest shareholder, Nantong Industrial Holdings Group Co., Ltd., holds 34.39% of the shares, totaling 279,994,660 shares[89]. Compliance and Governance - The company has established a governance structure including a shareholders' meeting, board of directors, supervisory board, and general manager[129]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that its financial statements accurately reflect its financial position and operating results[134]. - The company has not reported any major litigation or arbitration matters during the reporting period[73].

精华制药集团股份有限公司 2024年半年度非经营性资金占用及其他关联资金往来汇总表 | | | | 上市公司核算的会计 | | 2024年度 | 2024年度 | 2024年度 | 2024年期末 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 非经营性资金占用 | 资金往来方名称 | 占用方与上市公司的关联关系 | | 2024年期初占 | 往来累计发 | 往来资金的 | 偿还累计发 | 占用资金余 | 占用形成原因 | 占用性质 | | | | | 科目 | 用资金余额 | 生金额（不 | 利息（如 | 生金额 | 额 | | | | | | | | | 含利息） | 有） | | | | | | 现大股东及其附属企业 | - | - | - | - | - | - | - | - | - | - | | 小计 | - | - | - | - | - | - | - | - | - | - | | 前大股东及其附属企业 | - | - | - | - | - | - | - | - | - | - | ...

精华制药集团股份有限公司（以下简称"公司"）已于2024年4月19日在巨 潮资讯网上披露了《关于参加独立董事培训并取得独立董事资格证书的承诺函》， 张晓梅女士被提名为公司第六届董事会独立董事候选人，并承诺："本人参加最 近一次独立董事培训并将取得深圳证券交易所认可的独立董事资格证书。" 近日，公司接到张晓梅女士的通知，张晓梅女士于2024年5月21日至2024年8 月5日参加了由深圳证券交易所举办的上市公司独立董事培训班学习，取得上市 公司独立董事培训证明。 证券代码：002349 证券简称：精华制药 公告编号：2024-027 精华制药集团股份有限公司 关于独立董事候选人取得独立董事资格证书的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 特此公告。 精华制药集团股份有限公司董事会 2024 年 8 月 20 日 ...

证券代码：002349 证券简称：精华制药 公告编号：2024-026 精华制药集团股份有限公司 关于公司产品苯巴比妥片通过仿制药一致性评价的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假记载、 误导性陈述或者重大遗漏承担责任。 近日，精华制药集团股份有限公司（以下简称"公司"）收到国家药品监督管理 局核准签发的苯巴比妥片《药品补充申请批准通知书》，该产品通过仿制药质量和疗 效一致性评价。现就相关情况公告如下： 一、基本情况 通知书编号：2024B03723 受理号：CYHB2350703 有效期：36 个月 药品名称：通用名称：苯巴比妥片 英文名/拉丁名：Phenobarbital Tablets 原药品批准文号：国药准字 H32020797 药品注册标准编号：YBH19412024 剂型：片剂 疗效与日本原研产品基本一致，公司成为国内苯巴比妥片第二家通过仿制药质量和 疗效一致性评价的企业。 三、对公司的影响及风险提示 规格：30mg 包装规格：每板 10 片，每盒 3 板 申请内容：仿制药质量和疗效一致性评价 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品通 ...